Deutetrabenazine is the deuterium labeled Tetrabenazine, which is a VMAT-inhibitor used for treatment of hyperkinetic movement disorder.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||10 mM in DMSO|
Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.
Fernandez HH, et al. Neurology. 2017 May 23;88(21):2003-2010. PMID: 28446646.
Deutetrabenazine-Not a Revolution but Welcome Evolution for Treating Chorea in Huntington Disease.
Reilmann R, et al. JAMA Neurol. 2016 Dec 1;73(12):1404-1406. PMID: 27749952.
Photochlor is a lipophilic, second-generation, chlorin-based photosensitizer.
AMPPD is a new biochemistry ultrasensitive alkaline phosphatase substrate.
DM1-SMCC is DM1 with a reactive linker SMCC, which can react with antibody to make ADC.
Mitapivat is a potent human R-type pyruvate kinase (PKR) inhibitor.
VH-298 is a potent VHL inhibitor that stabilizes HIF-α and elicits a hypoxic response via a different mechanism, with a Kd value of 80 to 90 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.